Loading market data...
Fri, 30 Oct 2026
07:02:22 am
Fri, 30 Oct 2026
07:02:22 am
Rudransh Sangwan
Published at: October 30, 2026, 4:06 AM
Synopsis
Bliss GVS Pharma Q2 FY27 results show revenue rising 37.3% to ₹261.13 crore, EBITDA jumping 161.4% and net profit increasing 196%.
Bliss GVS Pharma reported a 37.3% year-on-year increase in standalone revenue to ₹261.13 crore in Q2 FY27. EBITDA surged 161.4% to ₹8.06 crore, while the EBITDA margin expanded to 25.71% from 12.58% a year earlier.
| Financial Metric | Q2 FY27 | Q2 FY26 | Growth |
|---|---|---|---|
| Revenue | ₹261.13 crore | ₹190.23 crore | +37.3% |
| EBITDA | ₹8.06 crore | ₹3.08 crore | +161.4% |
| EBITDA Margin | 25.71% | 12.58% | Improved |
| Net Profit | ₹73.57 crore | ₹24.79 crore | +196% |
Standalone net profit rose 196% to ₹73.57 crore, supported partly by a ₹41.09 crore exceptional gain from reversing an impairment provision on investments in its wholly owned subsidiary, Bliss GVS International Pte. Ltd.
Even excluding the exceptional item, profit before tax and exceptional items increased 71.2% year-on-year to ₹57.28 crore, indicating improvement in underlying performance.
Anupam Rasayan India Limited acquired a 50.07% stake in Bliss GVS Pharma during the quarter and became its holding company and promoter on September 28, 2026.
| Period | Return |
|---|---|
| 1 day | -4.99% |
| 5 days | +5.94% |
| 1 month | -4.22% |
| 6 months | +154.68% |
| 1 year | +347.81% |
| 5 years | +514.53% |
Key takeaway: Bliss GVS Pharma recorded strong revenue and EBITDA growth in Q2 FY27, although its sharp standalone net profit increase was partly driven by a one-time impairment reversal.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
Motilal Oswal Q2 FY27 results show net profit rising 198% to ₹1,080 crore, revenue increasing 64% to ₹3,040 crore and EBITDA margin reaching 60.37%.
Alivus Life Sciences Q2 FY27 results show net profit rising 51.3% to ₹196.8 crore, revenue growing 16% to ₹682 crore and EBITDA margin reaching 38.
Thyrocare Q2 FY27 revenue rose 25.1% to ₹270.81 crore, while net profit fell 66.9% to ₹15.89 crore amid a ₹44.98 crore impairment loss.
Patel Retail will invest ₹2 crore to add 20,000 sq ft to its Ambernath distribution centre, increasing covered area to 84,000 sq ft.
Shadowfax Technologies Q2 FY27 results show revenue growth of 56.6% to ₹1,537.70 crore and a 422% jump in net profit to ₹67.95 crore.
